Yahyapour Rasoul, Shabeeb Dheyauldeen, Cheki Mohsen, Musa Ahmed Eleojo, Farhood Bagher, Rezaeyan Abolhasan, Amini Peyman, Fallah Hengameh, Najafi Masoud
School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.
Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Science (International Campus), Tehran, Iran.
Curr Mol Pharmacol. 2018;11(4):285-304. doi: 10.2174/1874467211666180619125653.
Nowadays, ionizing radiations are used for various medical and terroristic aims. These purposes involve exposure to ionizing radiations. Hence, people are at risk for acute or late effects. Annually, millions of cancer patients undergo radiotherapy during their course of treatment. Also, some radiological or nuclear events in recent years pose a threat to people, hence the need for radiation mitigation strategies. Amifostine, the first FDA approved radioprotector, has shown some toxicities that limit its usage and efficiency. Due to these side effects, scientists have researched for other agents with less toxicity for better radioprotection and possible mitigation of the lethal effects of ionizing radiations after an accidental exposure. Flavonoids have shown promising results for radioprotection and can be administered in higher doses with less toxicity. Studies for mitigation of ionizing radiation-induced toxicities have concentrated on natural antioxidants. Detoxification of free radicals, management of inflammatory responses and attenuation of apoptosis signaling pathways in radiosensitive organs are the main mechanisms for radiation protection and mitigation with flavonoids and natural antioxidants. However, several studies have proposed that a combination in the form of some antioxidants may alleviate radiation toxicities more effectively in comparison to a single form of antioxidants.
In this review, we focus on recent findings about natural radioprotectors and mitigators which are clinically applicable for radiotherapy patients, as well as injured people in possible radiation accidents.
如今,电离辐射被用于各种医疗和恐怖主义目的。这些目的涉及暴露于电离辐射。因此,人们面临急性或晚期效应的风险。每年,数以百万计的癌症患者在治疗过程中接受放射治疗。此外,近年来的一些放射或核事件对人们构成威胁,因此需要辐射缓解策略。氨磷汀是首个获得美国食品药品监督管理局(FDA)批准的放射防护剂,但已显示出一些毒性,限制了其使用和效果。由于这些副作用,科学家们一直在研究其他毒性较小的药物,以实现更好的放射防护,并在意外暴露后可能减轻电离辐射的致死效应。黄酮类化合物在放射防护方面已显示出有前景的结果,并且可以以较低的毒性给予更高的剂量。减轻电离辐射诱导毒性的研究主要集中在天然抗氧化剂上。自由基解毒、炎症反应管理以及放射敏感器官中凋亡信号通路的减弱是黄酮类化合物和天然抗氧化剂进行辐射防护和缓解的主要机制。然而,多项研究表明,与单一形式的抗氧化剂相比,某些抗氧化剂组合可能更有效地减轻辐射毒性。
在本综述中,我们关注天然放射防护剂和缓解剂的最新研究成果,这些成果在临床上适用于放疗患者以及可能发生辐射事故中的受伤人员。